Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

NK Cell–Specific CDK8 Deletion Enhances Antitumor Responses

Agnieszka Witalisz-Siepracka, Dagmar Gotthardt, Michaela Prchal-Murphy, Zrinka Didara, Ingeborg Menzl, Daniela Prinz, Leo Edlinger, Eva Maria Putz and Veronika Sexl
Agnieszka Witalisz-Siepracka
Institute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dagmar Gotthardt
Institute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michaela Prchal-Murphy
Institute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zrinka Didara
Institute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingeborg Menzl
Institute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Prinz
Institute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leo Edlinger
Institute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva Maria Putz
Institute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Veronika Sexl
Institute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna, Austria.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: veronika.sexl@vetmeduni.ac.at
DOI: 10.1158/2326-6066.CIR-17-0183 Published April 2018
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Loss of CDK8 is dispensable for NK-cell development and maturation. A, Sorted Cdk8fl/fl and Cdk8fl/flNcr1Cre splenic NK cells (left) or poly(I:C)-treated Cdk8fl/fl and Cdk8fl/flMx1Cre splenocytes (right) were isolated and the protein level of CDK8 was analyzed by Western blot. B, Frequency of Lin−(CD3−CD19−Ly-6G−Ter119−) CD122+ NK cells in bone marrow and (C) percentages of CD3−NKp46+ NK cells in the spleen were assessed by flow cytometry. D, Bone marrow Lin−CD122+ cells were further divided into NK precursors (NKPs: NKp46−NK1.1−), immature NK cells (iNKs: NKp46−NK1.1+), and mature NK cells (mNKs: NKp46+NK1.1+). E, Splenic CD3−NKp46+ cells were analyzed for the expression of the maturation markers CD27 and CD11b. Shown are representative plots. The summarized data is presented in Supplementary Fig. S1. F, The abundance of KLRG1+, NKG2D+, and DNAM-1+ cells among CD3−NKp46+ NK cells was assessed in the spleen of Cdk8fl/fl, Cdk8fl/flNcr1Cre, and poly(I:C)-treated Cdk8fl/fl and Cdk8fl/flMx1Cre mice. Shown are representative histograms. The summarized data are presented in Supplementary Table S1. B–E, Bar graphs and values on the plots represent mean ± SEM of 2 independent experiments; n = 6–7.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    CDK8-deficient NK cells show an increased cytotoxic capacity. A and B, IL2-expanded Cdk8fl/fl and Cdk8fl/flNcr1Cre NK cells were stimulated with IL12 or IL15 for 2 hours, and the expression of (A) CDK8, pSTAT1–S727, and total STAT1 and (B) CDK19 was analyzed by Western blot. C, MACS-purified Cdk8fl/fl and Cdk8fl/flNcr1Cre NK cells were plated in IL2 and the cell numbers were determined daily by manual cell counting using a Neubauer chamber. Symbols and error bars represent mean cell number ± SEM of technical triplicates from 1 out of 2 independent experiments with similar outcome. D, Cdk8fl/fl and Cdk8fl/flNcr1Cre splenocytes were stimulated with anti-NK1.1, IL2 + IL12, or IL2 + IL12 + IL15 for 4 hours and the percentage of IFNγ+ CD3−NKp46+ NK cells was analyzed by flow cytometry. Bar graph represents mean percentage of IFNγ+ NK cells ± SEM from 2 to 3 independent experiments; n = 4–6 per group. E, IL2 expanded Cdk8fl/fl and Cdk8fl/flNcr1Cre NK cells were stimulated with IL12 or IL15 for 2 hours and the expression of perforin and GZMB was analyzed by Western blot. F, Cdk8fl/fl and Cdk8fl/flNcr1Cre splenocytes were stimulated with IL2 + IL12 or IL2 + IL12 + IL15 for 4 hours and the expression of perforin and GZMB in CD3−NKp46+ cells was analyzed by intracellular staining. Representative histograms were overlaid. Bar graph represents mean MFI of perforin in NK cells or percentage of GZMB+ NK cells ± SEM from 2 independent experiments; n = 4 per group. G, IL2-expanded Cdk8fl/fl and Cdk8fl/flNcr1Cre NK cells were incubated for 3 to 4 hours with CFSE-stained YAC-1, B16F10, or v-abl+ target cells in effector-to-target ratios of 10:1, 5:1, and 1:1. The specific lysis of target cells was assessed by flow cytometry and a representative graph out of 2 independent experiments is shown. Symbols and error bars represent mean ± SEM of technical triplicates. *, P < 0.05; **, P < 0.01.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Mice lacking CDK8 in NK cells show reduced B16F10 lung metastasis. A,Cdk8fl/fland Cdk8fl/flMx1Cre mice were treated with poly(I:C) as described in the Materials and Methods section. On day 16, 5 × 104 B16F10 melanoma cells were injected i.v. into the mice. After 23 days, the number of pulmonary tumor nodules was assessed. B, 5 × 104 B16F10 melanoma cells were injected i.v. into Cdk8fl/fl and Cdk8fl/flNcr1Cre mice. After 23 days, the number of tumor nodules in the lung was assessed. A, B, Shown are representative lung pictures (left) and bar graphs representing mean ± SEM from 3 independent experiments; n = 11–12. *, P < 0.05.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Loss of CDK8 in NK cells results in improved antitumor response against v-abl+ leukemic cells. Cdk8fl/fl and Cdk8fl/flNcr1Cre mice were injected s.c. with 106 v-abl+ cells and after 10 days the tumor weight was assessed and tumor infiltrating NK cells were analyzed by flow cytometry. Shown are (A) representative tumor pictures and (B) bar graph representing mean tumor weight relative to body weight ± SEM from 2 independent experiments; n = 12–15. C, Representative plots of tumor infiltrating CD3−NKp46+ cells pregated on CD19− cells from Cdk8fl/fl (left panel) and Cdk8fl/flNcr1Cre mice (right panel) are shown and (D) their percentage among CD19− cells is presented as bar graph showing mean ± SEM from 2 independent experiments; n = 11. E and F, Tumor single-cell suspensions were left untreated or stimulated with IL2 + IL12 + IL15 for 4 hours and the percentage of IFNγ+CD3−NKp46+ NK cells was analyzed by flow cytometry. E, Representative histograms of unstimulated and stimulated tumor samples were overlaid. F, The bar graph represents mean percentage of IFNγ+ NK cells ± SEM from 1 experiment; n = 4 per group; *, P < 0.05; **, P < 0.01.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Loss of CDK8 in NK cells provides a survival benefit in a chronic leukemia model. Newborn Cdk8fl/fl (n = 10) and Cdk8fl/flNcr1Cre (n = 8) mice were injected s.c. with a replication-incompetent ecotropic retrovirus encoding for v-abl (A-MuLV). A, The Kaplan–Meier plot summarizes 2 independent experiments. B, The spleen/body weight ratio and the white blood cell count (WBC) at the survival endpoint are represented by bar graphs showing mean ± SEM of 2 independent experiments. C, Representative plots of bone marrow–infiltrating B cells (CD19+B220+) are shown, and the values represent mean ± SEM of one representative out of 2 independent experiments (n = 4–5). D, H&E stains of bone marrow from leukemia-bearing Cdk8fl/fl and Cdk8fl/flNcr1Cre mice were performed at the disease endpoint. E, The frequency of CD3−NKp46+ NK and CD3+ T cells amongst splenic, bone marrow or blood lymphocytes of leukemia-bearing mice at the disease endpoint were determined by flow cytometry. Bar graph represents mean ± SEM of one representative out of 2 independent experiments (n = 4–5). *, P < 0.05.

Additional Files

  • Figures
  • Supplementary Data

    • Figure S1 - Quantification of NK cell numbers and their maturation stages from Fig. 1
    • Table S1 - Quantification of frequency and expression of receptors from Fig. 1F
    • Figure S2 - S2. Quantification of perforin and granzyme B western blot from Fig. 2 and ex vivo cytotoxicity assay.
PreviousNext
Back to top
Cancer Immunology Research: 6 (4)
April 2018
Volume 6, Issue 4
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
NK Cell–Specific CDK8 Deletion Enhances Antitumor Responses
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
NK Cell–Specific CDK8 Deletion Enhances Antitumor Responses
Agnieszka Witalisz-Siepracka, Dagmar Gotthardt, Michaela Prchal-Murphy, Zrinka Didara, Ingeborg Menzl, Daniela Prinz, Leo Edlinger, Eva Maria Putz and Veronika Sexl
Cancer Immunol Res April 1 2018 (6) (4) 458-466; DOI: 10.1158/2326-6066.CIR-17-0183

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
NK Cell–Specific CDK8 Deletion Enhances Antitumor Responses
Agnieszka Witalisz-Siepracka, Dagmar Gotthardt, Michaela Prchal-Murphy, Zrinka Didara, Ingeborg Menzl, Daniela Prinz, Leo Edlinger, Eva Maria Putz and Veronika Sexl
Cancer Immunol Res April 1 2018 (6) (4) 458-466; DOI: 10.1158/2326-6066.CIR-17-0183
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • CD28 Mutation Enhances CAR T-cell Function
  • ICV-Delivered CD19-CAR T Cells for CNS and Systemic Lymphoma
  • Activin A Mediates Radiation-Induced Antitumor Immunity
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement